137 related articles for article (PubMed ID: 21521023)
21. CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.
Fanciullino R; Farnault L; Donnette M; Imbs DC; Roche C; Venton G; Berda-Haddad Y; Ivanov V; Ciccolini J; Ouafik L; Lacarelle B; Costello R
Blood Adv; 2018 Mar; 2(5):462-469. PubMed ID: 29490977
[TBL] [Abstract][Full Text] [Related]
22. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.
Bhatla D; Gerbing RB; Alonzo TA; Conner H; Ross JA; Meshinchi S; Zhai X; Zamzow T; Mehta PA; Geiger H; Perentesis J; Davies SM
Br J Haematol; 2009 Feb; 144(3):388-94. PubMed ID: 19036079
[TBL] [Abstract][Full Text] [Related]
23. Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift?
Serdjebi C; Ciccolini J; Fina F; Delarue A; Verschuur A; Lacarelle B; Ouafik L; André N
Pharmacogenet Genomics; 2014 Oct; 24(10):527-9. PubMed ID: 25003625
[TBL] [Abstract][Full Text] [Related]
24. Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
Gusella M; Pasini F; Bolzonella C; Meneghetti S; Barile C; Bononi A; Toso S; Menon D; Crepaldi G; Modena Y; Stievano L; Padrini R
Br J Clin Pharmacol; 2011 Mar; 71(3):437-44. PubMed ID: 21284703
[TBL] [Abstract][Full Text] [Related]
25. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
[TBL] [Abstract][Full Text] [Related]
26. Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene.
Beauséjour CM; Eliopoulos N; Momparler L; Le NL; Momparler RL
Cancer Gene Ther; 2001 Sep; 8(9):669-76. PubMed ID: 11593336
[TBL] [Abstract][Full Text] [Related]
27. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells.
Momparler RL; Eliopoulos N; Bovenzi V; Létourneau S; Greenbaum M; Cournoyer D
Cancer Gene Ther; 1996; 3(5):331-8. PubMed ID: 8894252
[TBL] [Abstract][Full Text] [Related]
28. [Ara-C].
Onozawa M; Teshima T
Nihon Rinsho; 2015 Feb; 73 Suppl 2():623-7. PubMed ID: 25831835
[No Abstract] [Full Text] [Related]
29. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.
Hummel-Eisenbeiss J; Hascher A; Hals PA; Sandvold ML; Müller-Tidow C; Lyko F; Rius M
Mol Pharmacol; 2013 Sep; 84(3):438-50. PubMed ID: 23814180
[TBL] [Abstract][Full Text] [Related]
30. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy.
Grau JJ; Caballero M; Monzó M; Muñoz-García C; Domingo-Domenech J; Navarro A; Conill C; Campayo M; Bombí JA
J Surg Oncol; 2008 Aug; 98(2):130-4. PubMed ID: 18537153
[TBL] [Abstract][Full Text] [Related]
31. Long term cultured HL-60 cells are intrinsically resistant to Ara-C through high CDA activity.
Tang J; Xie X; Zhang X; Qiao X; Jiang S; Shi W; Shao Y; Zhou X
Front Biosci (Landmark Ed); 2012 Jan; 17(2):569-74. PubMed ID: 22201761
[TBL] [Abstract][Full Text] [Related]
32. Potential mechanisms of resistance to cytarabine in AML patients.
Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
[TBL] [Abstract][Full Text] [Related]
33. Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.
Lam SW; van der Noort V; van der Straaten T; Honkoop AH; Peters GJ; Guchelaar HJ; Boven E
Pharmacol Res; 2018 Feb; 128():122-129. PubMed ID: 28827188
[TBL] [Abstract][Full Text] [Related]
34. Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo.
Yoshida T; Endo Y; Obata T; Kosugi Y; Sakamoto K; Sasaki T
Drug Metab Dispos; 2010 Oct; 38(10):1814-9. PubMed ID: 20587622
[TBL] [Abstract][Full Text] [Related]
35. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
[TBL] [Abstract][Full Text] [Related]
36. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
Metharom E; Galettis P; Manners S; Jelinek M; Liauw W; de Souza PL; Hoskins JM; Links M
Asia Pac J Clin Oncol; 2011 Mar; 7(1):65-74. PubMed ID: 21332653
[TBL] [Abstract][Full Text] [Related]
37. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
Sugiyama E; Kaniwa N; Kim SR; Kikura-Hanajiri R; Hasegawa R; Maekawa K; Saito Y; Ozawa S; Sawada J; Kamatani N; Furuse J; Ishii H; Yoshida T; Ueno H; Okusaka T; Saijo N
J Clin Oncol; 2007 Jan; 25(1):32-42. PubMed ID: 17194903
[TBL] [Abstract][Full Text] [Related]
39. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.
Serdjebi C; Milano G; Ciccolini J
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):665-72. PubMed ID: 25495470
[TBL] [Abstract][Full Text] [Related]
40. The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine.
Clarke ML; Damaraju VL; Zhang J; Mowles D; Tackaberry T; Lang T; Smith KM; Young JD; Tomkinson B; Cass CE
Mol Pharmacol; 2006 Jul; 70(1):303-10. PubMed ID: 16617163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
